Literature DB >> 25450307

Presynaptic effects of levodopa and their possible role in dyskinesia.

Eugene V Mosharov1, Anders Borgkvist, David Sulzer.   

Abstract

Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's Disease; dopamine; dyskinesia; levodopa; presynaptic; serotonin

Mesh:

Substances:

Year:  2014        PMID: 25450307      PMCID: PMC4314471          DOI: 10.1002/mds.26103

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  113 in total

Review 1.  Regulation of quantal size by presynaptic mechanisms.

Authors:  D Sulzer; E N Pothos
Journal:  Rev Neurosci       Date:  2000       Impact factor: 4.353

2.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines.

Authors:  T F Freund; J F Powell; A D Smith
Journal:  Neuroscience       Date:  1984-12       Impact factor: 3.590

Review 3.  Animal models of L-DOPA-induced dyskinesia: an update on the current options.

Authors:  H Iderberg; V Francardo; E Y Pioli
Journal:  Neuroscience       Date:  2012-03-21       Impact factor: 3.590

4.  Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine.

Authors:  M J Nirenberg; J Chan; Y Liu; R H Edwards; V M Pickel
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

5.  Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency.

Authors:  Roser Pons; Dimitris Syrengelas; Sotiris Youroukos; Irene Orfanou; Arqirios Dinopoulos; Bru Cormand; Aida Ormazabal; Angels Garzía-Cazorla; Mercedes Serrano; Rafael Artuch
Journal:  Mov Disord       Date:  2013-02-06       Impact factor: 10.338

6.  Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Authors:  Sylvia Navailles; Bernard Bioulac; Christian Gross; Philippe De Deurwaerdère
Journal:  Neurobiol Dis       Date:  2010-01-22       Impact factor: 5.996

7.  Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.

Authors:  S Sarre; N De Klippel; P Herregodts; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

Review 8.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

Review 9.  Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.

Authors:  Panagiotis Bargiotas; Spyridon Konitsiotis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

Review 10.  Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations.

Authors:  Manolo Carta; Elisabetta Tronci
Journal:  Front Neurol       Date:  2014-05-20       Impact factor: 4.003

View more
  20 in total

Review 1.  Dysregulation of striatal projection neurons in Parkinson's disease.

Authors:  Goichi Beck; Arun Singh; Stella M Papa
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

Review 2.  Synaptic plasticity may underlie l-DOPA induced dyskinesia.

Authors:  Anders Borgkvist; Ori J Lieberman; David Sulzer
Journal:  Curr Opin Neurobiol       Date:  2017-11-07       Impact factor: 6.627

Review 3.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

4.  Dopamine Triggers the Maturation of Striatal Spiny Projection Neuron Excitability during a Critical Period.

Authors:  Ori J Lieberman; Avery F McGuirt; Eugene V Mosharov; Irena Pigulevskiy; Benjamin D Hobson; Sejoon Choi; Micah D Frier; Emanuela Santini; Anders Borgkvist; David Sulzer
Journal:  Neuron       Date:  2018-07-26       Impact factor: 17.173

Review 5.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Unmasking the Effects of L-DOPA on Rapid Dopamine Signaling with an Improved Approach for Nafion Coating Carbon-Fiber Microelectrodes.

Authors:  Lingjiao Qi; Elina Thomas; Stephanie H White; Samantha K Smith; Christie A Lee; Leslie R Wilson; Leslie A Sombers
Journal:  Anal Chem       Date:  2016-08-03       Impact factor: 6.986

9.  Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.

Authors:  Renata P Lerner; Zisis Bimpisidis; Stergiani Agorastos; Sandra Scherrer; Stephen L Dewey; M Angela Cenci; David Eidelberg
Journal:  Neurobiol Dis       Date:  2016-08-17       Impact factor: 5.996

10.  Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.

Authors:  Kelly M Lohr; Merry Chen; Carlie A Hoffman; Miranda J McDaniel; Kristen A Stout; Amy R Dunn; Minzheng Wang; Alison I Bernstein; Gary W Miller
Journal:  Toxicol Sci       Date:  2016-06-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.